Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

• Published in: Journal for immunotherapy of cancer 2021-04, Vol.9 (4), p.e002224
• Main Authors: Zhang, Bo, Huang, Jing, Tang, Jialin, Hu, Sheng, Luo, Suxia, Luo, Zhiguo, Zhou, Fuxiang, Tan, Shiyun, Ying, Jieer, Chang, Qing, Zhang, Rui, Geng, Chengyun, Wu, Dawei, Gu, Xiangyong, Liu, Binlei
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antigens; Biodistribution; Biological activity; Biomarkers; Biopsy; Cancer; China; Combined Modality Therapy; COVID-19; Drug dosages; Female; Genetic engineering; Hematology; Herpes viruses; Herpesvirus 2, Human - genetics; Herpesvirus 2, Human - immunology; Herpesvirus 2, Human - pathogenicity; Humans; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Infections; Male; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasms - immunology; Neoplasms - therapy; Neoplasms - virology; Neutropenia; Oncolytic and Local Immunotherapy; Oncolytic Virotherapy - adverse effects; Oncolytic Viruses - genetics; Oncolytic Viruses - immunology; Oncolytic Viruses - pathogenicity; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Response Evaluation Criteria in Solid Tumors; Time Factors; Treatment Outcome; Tumors
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2020-002224

BackgroundOH2 is a genetically engineered oncolytic herpes simplex virus type 2 designed to selectively amplify in tumor cells and express granulocyte-macrophage colony-stimulating factor to enhance antitumor immune responses. We investigated the safety, tolerability and antitumor activity of OH2 as single agent or in combination with HX008, an anti-programmed cell death protein 1 antibody, in patients with advanced solid tumors.MethodsIn this multicenter, phase I/II trial, we enrolled patients with standard treatment-refractory advanced solid tumors who have injectable lesions. In phase I, patients received intratumoral injection of OH2 at escalating doses (106, 107 and 108CCID50/mL) as single agent or with fixed-dose HX008. The recommended doses were then expanded in phase II. Primary endpoints were safety and tolerability defined by the maximum-tolerated dose and dose-limiting toxicities (DLTs) in phase I, and antitumor activity assessed per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) and immune-RECIST in phase II.ResultsBetween April 17, 2019 and September 22, 2020, 54 patients with metastatic cancers were enrolled. Forty patients were treated with single agent OH2, and 14 with OH2 plus HX008. No DLTs were reported with single agent OH2 in phase I. Four patients, having metastatic mismatch repair-proficient rectal cancer or metastatic esophageal cancer, achieved immune-partial response, with two from the single agent cohort and two from the combination cohort. The duration of response were 11.25+ and 14.03+ months for the two responders treated with single agent OH2, and 1.38+ and 2.56+ months for the two responders in the combination cohort. The most common treatment-related adverse event (TRAE) with single agent OH2 was fever (n=18, 45.0%). All TRAEs were of grade 1–2, except one case of grade 3 fever in the 108CCID50/mL group. No treatment-related serious AEs occurred. Single agent OH2 induced alterations in the tumor microenvironment, with clear increases in CD3+ and CD8+ cell density and programmed death-ligand 1 expression in the patients’ post-treatment biopsies relative to baseline.ConclusionsIntratumoral injection of OH2 was well-tolerated, and demonstrated durable antitumor activity in patients with metastatic esophageal and rectal cancer. Further clinical development of OH2 as single agent or with immune checkpoint inhibitors in selected tumor types is warranted.